Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Genius Sports Limited (NYSE: GENI) was $10.56 for the day, up 0.86% from the previous closing price of $10.47. In other words, the price has increased by $0.86 from its previous closing price. On the day, 2.44 million shares were traded. GENI stock price reached its highest trading level at $10.605 during the session, while it also had its lowest trading level at $10.265.
Ratios:
Our analysis of GENI’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.71. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.43. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on April 22, 2025, Reiterated its Buy rating but revised its target price to $12 from $11 previously.
On April 21, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 06 ’25 when Stevens Eric bought 79,373 shares for $9.38 per share.
Davison Jack bought 100,388 shares of GENI for $876,939 on Jan 17 ’25. On Jan 10 ’25, another insider, Davison Jack, who serves as the Officer of the company, bought 8,202 shares for $8.73 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GENI now has a Market Capitalization of 2458051328 and an Enterprise Value of 2111538176. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.34 while its Price-to-Book (P/B) ratio in mrq is 3.90. Its current Enterprise Value per Revenue stands at 4.133 whereas that against EBITDA is -82.421.
Stock Price History:
The Beta on a monthly basis for GENI is 1.93, which has changed by 1.034682 over the last 52 weeks, in comparison to a change of 0.07545352 over the same period for the S&P500. Over the past 52 weeks, GENI has reached a high of $11.16, while it has fallen to a 52-week low of $4.91. The 50-Day Moving Average of the stock is 9.50%, while the 200-Day Moving Average is calculated to be 26.11%.
Shares Statistics:
GENI traded an average of 3.36M shares per day over the past three months and 3131710 shares per day over the past ten days. A total of 239.82M shares are outstanding, with a floating share count of 216.07M. Insiders hold about 9.90% of the company’s shares, while institutions hold 76.51% stake in the company. Shares short for GENI as of 1743379200 were 29830707 with a Short Ratio of 8.87, compared to 1740700800 on 30922498. Therefore, it implies a Short% of Shares Outstanding of 29830707 and a Short% of Float of 14.050001000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
